Login to Your Account



Pharma: clinic roundup


Thursday, March 13, 2014

Pfizer Inc., of New York, reported that detailed results of the Community-Acquired Pneumonia Immunization Trial in Adults, or CAPiTA, which enrolled approximately 85,000 subjects, demonstrated that Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) prevented a first episode of vaccine-type community-acquired pneumonia (CAP) in adults 65 years of age and older, the study’s primary endpoint. Pfizer said the trial was the first in adults to demonstrate a significant reduction in vaccine-type pneumococcal CAP and non-bacteremic/non-invasive vaccine-type pneumococcal CAP.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription